Business Description
MetaVia Inc
NAICS : 325412
SIC : 2834
ISIN : US36870A1088
Description
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 94.83 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 71.4 | |||||
| 3-Year EPS without NRI Growth Rate | 71.7 | |||||
| 3-Year FCF Growth Rate | 72.8 | |||||
| 3-Year Book Growth Rate | -80.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 29.35 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.21 | |||||
| 9-Day RSI | 37.8 | |||||
| 14-Day RSI | 39.36 | |||||
| 3-1 Month Momentum % | -58.72 | |||||
| 6-1 Month Momentum % | -67.97 | |||||
| 12-1 Month Momentum % | -85.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.55 | |||||
| Quick Ratio | 1.55 | |||||
| Cash Ratio | 1.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -326.9 | |||||
| Shareholder Yield % | 0.45 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -226.12 | |||||
| ROA % | -127.46 | |||||
| ROIC % | -1850.73 | |||||
| 3-Year ROIIC % | -1170.8 | |||||
| ROC (Joel Greenblatt) % | -13614.98 | |||||
| ROCE % | -236.08 | |||||
| Moat score | 5 | |||||
| Tariff score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.3 | |||||
| Price-to-Tangible-Book | 1.3 | |||||
| EV-to-EBIT | -0.06 | |||||
| EV-to-Forward-EBIT | -0.03 | |||||
| EV-to-EBITDA | -0.06 | |||||
| EV-to-FCF | -0.07 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Price-to-Net-Cash | 1.65 | |||||
| Earnings Yield (Greenblatt) % | -1666.67 | |||||
| FCF Yield % | -178.12 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers